Immuneering presents AACR data linking atebimetinib plus mGnP to longer survival in pancreatic cancer study

Bitget2026/09/28 11:32

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Immuneering presented new exploratory clinical data at the 2026 AACR Conference on Pancreatic Cancer on atebimetinib with chemotherapy.
Analyses linked maintaining body weight during treatment to longer survival versus weight loss, supporting a potential cachexia-related benefit.
Survival appeared similar across moderate versus deeper tumor shrinkage, suggesting any measurable reduction may matter more than response depth.
Findings reinforce the investment case for the ongoing Phase 3 MAPKeeper 301 trial in first-line pancreatic cancer, which is enrolling patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280730PRIMZONEFULLFEED9834261) on September 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Immuneering presents AACR data linking atebimetinib plus mGnP to longer survival in pancreatic cancer study

You may also like

Crypto prices